📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
43 announcements match the current filters (relevance ≥ 5).
HCG Earnings Call Transcript: Discussing Strategy & Long-Term Growth
Healthcare Global Enterprises Limited (HCG) held an earnings call on December 4, 2025, to discuss the company's business strategy and long-term growth plans. HCG operates 25 hospitals across 10 states and 19 cities, holding a leading position in 16 of those cities. The company has a comprehensive infrastructure with 2,500 beds and the largest LINAC installation base of 38 in India. HCG's revenue increased 15-fold and EBITDA grew 16-fold, with CAGRs of 15% and 18% respectively.
Key Highlights
HCG operates 25 hospitals across 10 states and 19 cities.
HCG has a LINAC installation base of 38 in the country.
HCG has a gross mortality rate of 0.9%.
HCG's revenue increased 15-fold.
EBITDA grew at a CAGR of 18%.
👀 What to Watch
Review the earnings call transcript to understand HCG's strategic direction and growth plans. Monitor the company's performance in key markets and its ability to maintain its clinical outcomes.
HCG Unveils Growth Strategy: Targets Oncology Market with 25 Hospitals and 18% EBITDA Margin
Healthcare Global Enterprises (HCG) has established itself as India's largest oncology-focused hospital chain, growing revenue 24x from INR 918 Mn in FY10 to INR 22,228 Mn in FY25. The company currently operates 25 hospitals with 2,500+ beds and maintains a leading market position in 16 of its 19 operational cities. With an adjusted EBITDA margin of 18% and backing from KKR, HCG is positioned to capture the 13-14% annual growth in the Indian oncology market, driven by a significant demand-supply gap in cancer care infrastructure.
Key Highlights
Largest oncology network in India with 25 hospitals, 38 LINACs, and 400+ oncologists across 19 cities.
Revenue reached INR 22,228 Mn in FY25 with an adjusted EBITDA of INR 3,963 Mn, reflecting a 27% CAGR since FY10.
Maintains industry-leading clinical outcomes with a mortality rate of 0.9% and leading positions in 16 out of 19 cities.
Oncology market in India is growing at 13-14%, significantly faster than the 10-11% growth seen in multispecialty hospitals.
Strategic shift from partnership models to owned models has helped stabilize margins at 18%.
👀 What to Watch
Investors should focus on the company's ability to transition 'emerging' centers into 'mature' ones to further boost EBITDA margins. The specialized focus and KKR's backing provide a strong competitive moat in a high-demand, underserviced healthcare segment.
HCG appoints Dr. Manish Mattoo as interim CFO, effective Dec 1, 2025
Healthcare Global Enterprises Limited (HCG) has appointed Dr. Manish Mattoo, Executive Director and CEO, as the interim Chief Financial Officer (CFO) and Key Managerial Personnel, effective December 1, 2025. This appointment follows the recommendation of the Audit Committee and the Nomination and Remuneration Committee. Dr. Mattoo's term will last until a new CFO is appointed by the Board. He previously served as Regional Chief Executive Officer at Apollo Hospitals, overseeing 2000+ beds.
Key Highlights
Dr. Manish Mattoo appointed as interim CFO effective December 1, 2025
Dr. Mattoo previously led a team of over 6,000 associates at Apollo Hospitals.
Dr. Mattoo oversaw 2000+ beds as Regional CEO at Apollo Hospitals.
Board meeting concluded at 2:55 p.m. (IST) on December 01, 2025.
👀 What to Watch
Investors should monitor the appointment of a permanent CFO and assess any impact on the company's financial strategy. This is a transitional appointment and is unlikely to cause any immediate change.
